Skip to main content
CRVO logo

CRVO · CervoMed Inc. · Financials

Track CRVO — free
$2.34 +0.03 (+1.30%)
Market Cap
$34.93M
Shares
15.12M
Volume · Oct 20 91.66K Avg daily vol (3M) 292.1K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Revenue
$4.01M -58.9%
FY2025 Revenue FY2010–FY2025
Net Income
-$26.97M -65.5%
FY2025 Net Income FY2010–FY2025
Gross Margin
100% +63pp
FY2013 Gross Margin FY2010–FY2013
Operating Margin
-706.22% -519pp
FY2025 Operating Margin FY2010–FY2025
Diluted EPS
$3,058,336.50 +4.7%
FY2022 Diluted EPS FY2016–FY2022
Operating Cash Flow
-$23.45M -41.9%
FY2025 Operating Cash Flow FY2010–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
$331.3K $4.01M $9.74M $7.14M $0 — — — — — — — — $71.67K $374.54K $570.48K $40.19K
— — — — — — — — — — — — — $0 $235.8K $2.31M $210.39K
$71.67K — — — — — — — — — — — — $71.67K $138.74K -$1.74M -$170.2K
— — — — — — — — — — — — — 100% 37.04% -304.68% -423.51%
$21.33M $21.82M $18.8M $8.44M $1.34M $8.5M $9.43M $6.62M $5.75M $5.09M $7.25M $3.88M $2.86M $342.92K — $0 —
$10.17M $10.48M $9.17M $6.52M $2.14M $7.45M $6.44M $4.83M $6.17M $6.19M $11.09M $2.52M $4.76M $7.33M $4.57M $6.7M $2.17M
— — — — — — — — — — — $0 $554.34K — — — —
— — — — $0 $93.42K $103.17K — — — — $23.27K $566.26K $116.45K $164.04K $69.81K $49.67K
$31.5M $32.3M $27.97M $14.96M $3.48M — — — — — — $23.83M $14.61M $12.8M $11.93M $14.69M $7.47M
-$31.16M -$28.29M -$18.23M -$7.81M -$3.48M -$24.68M -$15.97M -$11.55M -$18.96M -$11.35M -$18.37M -$6.41M -$14.61M -$12.8M -$11.79M -$16.43M -$7.64M
— -706.22% -187.18% -109.35% — — — — — — — — — -17855.55% -3148.34% -2879.94% -19002.6%
— — — — -$3.48M -$24.58M -$15.87M — — — — -$6.38M -$14.05M -$12.68M -$11.63M -$16.36M -$7.59M
— — — $0 $587 — — — $3000 $100K $37K $313.12K $273.5K $126.48K -$167.89K $30.54K —
$812.01K $1.34M $1.94M $219.43K $62.23K — — — — — — — — — — — —
$815.05K $1.33M $1.94M $5.64M -$2.33M — — — — — — $6357 -$2.56M $9.83M -$4.94M -$6.21M -$772.65K
— — — — -$15.59M -$24.54M -$15.86M -$11.47M -$18.81M -$2.42M -$18.4M -$6.72M -$17.17M -$2.97M — — —
— $0 — — $0 -$443.89K -$1.68M $332.89K -$437.29K -$1.06M -$364.8K $0 -$2.82M $0 $0 — —
-$30.35M -$26.97M -$16.29M -$2.17M -$5.8M -$24.1M -$14.19M -$11.8M -$18.37M -$1.36M -$18.04M -$6.72M -$14.35M -$2.46M -$6.87M -$22.64M -$8.41M
— -673.06% -167.29% -30.4% — — — — — — — — — -3429.68% -1833.94% -3967.89% -20925.14%
— — — — — — — — — — — — — $6401 $19.08K — —
— — — — — -$24.1M -$16.14M -$11.8M -$26.62M -$2.62M -$18.04M -$23.82M -$14.35M -$2.64M -$7.37M -$23.03M —
-$30.35M -$27.02M -$16.23M -$2.17M -$15.63M -$24.1M — — — — — — — — — — —
USD/shares -$3.22 -$2.98 -$2.02 -$0.82 -$11.20 -$18.57 -$22.50 -$132.00 -$615.75 -$237.00 -$132.00 — — — — — —
USD/shares — — — — $3,058,336.50 $2,920,288.50 $4,037,397,975.00 $502,988,175.00 $243,172,575.00 -$2,183.25 -$132.00 — — — — — —
shares — 9.04M 8.07M 2.66M 518.14K — — — 43.23K 11.03K 136.44K 248.2K 190.66K — — 1.01M 769.24K
shares — — — — — — — — 43.23K 11.31K 136.44K 248.2K 190.66K 35.29K 14.96K 1.35M 769.24K
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current portion of convertible notes payable 2023-12-31 USD 0 10-K filed 2024-03-29
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
—
Peer median 4.00×
EV/EBIT
—
Peer median 8.36×
P/E (TTM)
—
Peer median 3.50×

Peer medians compare against the 289 similar-size Biotechnology companies (of 559 listed).

Valuation over time computed as of each quarter's filing date

Key facts CIK 1053691 CUSIP 15713L109 13F (30d) 3 filings 3 filers Visit website Investor relations